Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
Manlhiot
Cedric
C
Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Pollock-Barziv
Stacey M
SM
Holmes
Claire
C
Weitzman
Sheila
S
Allen
Upton
U
Clarizia
Nadia A
NA
Ngan
Bo-Yee
BY
McCrindle
Brian W
BW
Dipchand
Anne I
AI
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D020031:Epstein-Barr Virus Infections / Q000517:prevention & control / Q000821:virology; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007223:Infant; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology / Q000821:virology; D008297:Male; D016016:Proportional Hazards Models; D012008:Recurrence; D018570:Risk Assessment; D016559:Tacrolimus / Q000008:administration & dosage; D013997:Time Factors; D019562:Viral Load; D055815:Young Adult
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus